A recent patient survey reveals that almost one in four people with multiple sclerosis in the U.K. are not aware of available treatments that could help delay the onset of disability, even though a clear majority put disability as a chief worry.
The report, funded by Sanofi Genzyme, was conducted by Adelphi Research UK via online questionnaires given 100 healthcare specialists, including neurologists, and 120 patients with all types of multiple sclerosis in 2016. Called “The Missing Pieces,” it reports that 83 percent of relapsing-remitting MS patients ranked preventing progression and disability as their primary concern. However, 24 percent of those who took part in the survey reported not being aware of treatments that might work to delay MS onset and progressive loss of function.
Only 21 percent of MS patients said they were actually receiving disease-modifying treatments (DMTs), potentially one of the lowest rates in Europe.
Respondents were from England (85 percent), Scotland (7 percent), Wales (7 percent), and Northern Ireland (1 percent), and included RRMS patients as well as those with secondary progressive and primary progressive MS.
“It is essential that treatments are considered in a timely manner to increase the likelihood of preventing long-term disability and ultimately to decrease the chance of MS impacting day-to-day quality of life,” Emma Matthews, MS Nurse Specialist at Northampton General Hospital, said in a release published by Sanofi on a company website.
“The UK MS community needs to create the right infrastructure to allow for earlier and effective conversations about treatment and disability,” Matthews added.
Specific to the United Kingdom, “The Missing Pieces” campaign aims to explore attitudes and behaviors around MS treatment in that country, and identify gaps in knowledge, understanding, conversations and treatment/care plans.
Among its major findings:
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?